Acquisition cost of antihypertensive drugs may hamper blood pressure (BP) control. We evaluated prescribing pattern, acquisition cost and cost-effectiveness relationship in 225 black hypertensives attending a tertiary clinic in a developing economy. BP control was achieved in 89 (39.6%), calcium channel blockers were used most frequently (28.4%), but the most cost-effective therapy was the diuretic co-amiloride.
The primary goal of hypertension (HBP) treatment is to reduce the total risk of cardiovascular morbidity and mortality. 1, 2 Targets for BP control reflect the 'safest' levels of BP in general, and also reflect the 'safest' levels in specific clinical settings such as those with comorbid diseases. 1, 2 The choice of antihypertensive therapy should, ideally, be evidence-based and comply with internationally acceptable guidelines. Nevertheless, an important consideration in the selection of drug therapy is the acquisition cost. This factor is even weightier in developing economies where the dual dilemmas of low per capita income and lack of medical insurance dampen the ideals of pharmacologic control of BP.
The objective of this study was to evaluate the prescribing pattern of antihypertensive drugs in a tertiary-care setting in a developing economy, assess the comparative acquisition cost of various therapies and discuss the extent of conformity to current international guidelines.
We conducted a cross-sectional descriptive study in the HBP clinic of the Lagos University Teaching Hospital, Lagos, Nigeria, over a 12-week period from October 2002 to December 2002. The inclusion criteria were diagnosed HBP and attendance at the clinic for at least 6 months. Two hundred and twentyfive serially attending patients with HBP were interviewed. Socio-demographic and clinical data were obtained. Patients were categorized by three income groups: low (o 20 000 i.e. o$150 at 135 ¼ $1), medium (X 20 000-200 000 i.e. X$150-$1500) and high income (X 200 000 i.e. X$1500).
Monotherapy was defined as use of a single medication containing only one antihypertensive agent. Combination drug therapy was defined as use of multiple antihypertensive agents either in fixed dose combination (FDC) or as separate agents.
The costs of antihypertensive medications were calculated as a function of the dosage prescribed and the prices in the hospital or community pharmacies. The monthly acquisition cost of antihypertensive therapy was then computed for each patient based on current cost of a 30-day supply considering average daily dose.
The BP of each patient was measured by conventional methods. 1 The average value of the two readings was taken as the current BP. Individuals with systolic BP (SBP) o140 mm Hg and diastolic BP (DBP) o90 mm Hg or mean arterial pressure less than 106.7 mm Hg were considered as having controlled HBP. 2 The cost-effectiveness relationship was calculated as the ratio of the annual mean cost to the proportion of patients with controlled HBP, for each pharmacological group. 3 The cost-effectiveness ratio (CER) allowed the cost per patient with controlled HBP to be described. Furthermore, a relative CER was described for each drug group, using the CER of the most cost-effective therapy as denominator (i.e. relative CER ¼ CER of therapy/CER of most cost-effective therapy in the study).
Other information (comorbid illness, reports of electrocardiograms (ECGs), echocardiograms, chest radiographs, urinalysis etc.) was obtained from the case records. Ischaemic heart disease (IHD) was diagnosed in the presence of a history of angina or previous diagnosis of coronary artery disease (based on exercise or rest ECG or coronary angiography) or previous acute coronary syndrome or ischaemic changes on resting ECG (unexplained by left ventricular 'strain pattern' in patients who had left ventricular hypertrophy (LVH) by voltage criteria). Chronic kidney disease (CKD) was defined based on 24 h urinary creatinine clearance o60 ml/min or serum creatinine persistently (on at least two occasions)4200 mmol/l with persistent dipstick proteinuria.
Data were analysed using EPIINFO 2002. Mean values were compared using analysis of variance for normally distributed data. For samples with unequal variance, the non-parametric Mann-Whitney U/Wilcoxon two-sample test was used. Proportions were compared using w 2 test. Statistical significance was assumed at a P-value o0.05.
Of the 225 patients we studied, there were 90 men (40%) and 135 women (60%). The mean age 7s.d. overall was 55.1712.4 years, and did not differ significantly between men and women (P ¼ 0.97). Of the 225 patients, 150 (66.7%) were low-income earners, 74 (32.9%) middle-income earners and 2 (0.4%) high-income earners. The duration of HBP ranged from 0.75 (9 months) to 40 years (mean 10.878.5 years). The duration of current hospital attendance ranged from 6 months to 34 years with the mean duration of attendance 7s.d. being 6.776.5 years.
Most of the patients (116; 51.6%) had compelling indications for the treatment of HBP. These comprised of persons with other comorbid conditions, target organ damage or both. Of the 71 patients (31.6%) with comorbid conditions (including multiple comorbidities), diabetes mellitus (DM) was present in 22, heart disease in 12 (previous heart failure ¼ 10, IHD ¼ 2), previous cerebrovascular disease (CVD) (13) and CKD (13). Fourteen had other miscellaneous conditions. LVH was present in 68 (30.2%) patients and occurred alone in 53 patients, but in combination with other comorbidities in 15. Patients with previous cerebrovascular accident and IHD were the oldest (mean age 64.8711.7 and 65.573.5 years, respectively), whereas the CKD patients were the youngest (mean age 42.4716.6 years).
Majority of the patients (174; 77.3%) were on combination therapy, whereas 51 (22.7%) were on monotherapy. The mean SBPs and DBPs at initial presentation were both significantly higher in those placed on combination therapy compared to patients on monotherapy (SBP: 163.4727.7 vs 148.2725.0; P ¼ 0.0002 and DBP: 105.0717.2 vs 94.0715; P ¼ 0.0001). The number of drugs prescribed for the 174 patients on combination therapy were as follows: two drugs -119 (52.9%), three drugs -52 (23.1%), four drugs -3 (1.3%). The majority (129/174; 74.3%) of the patients on combination therapy received single ingredient preparations as part of their prescription, whereas 45 (25.7%) were on FDC.
There were a total of 455 drug citations (each FDC medication had each constituent categorized). Overall, the frequency of drug prescriptions (alone or in combination) was as follows: calcium channel blocker (CCB) (129/455; 28.4%), FDC co-amiloride (95; 20.9%), angiotensin-converting enzyme inhibitor (ACEI) (70; 15.4%), a-methyldopa (a-MD) (70; 15.4%), b-blockers (65; 14.3%), FDC reserpine þ clopamide þ dihydro-ergocristine (13; 2.9%), FDC atenolol þ chlorthalidone (9; 2%) and prazosin, and a-blocker (4; 0.9%).
For patients on monotherapy, CCBs and ACEIs were most frequently prescribed (16/51 and 10/51, respectively), whereas for two drug combination therapy, a-MD with co-amiloride (29/119), CCB with co-amiloride (24/119) and ACEI with CCB (24/119) were most frequently prescribed. With specific reference to ACEI utilization, 15/22 (68.2%) patients with type II DM, 7/10 (70%) with CKD, 4/13 (31%) with CVD, 5/10 (50%) with previous heart failure (HF) and 27/68 (40%) of those with LVH were on ACEI therapy.
Overall, 89 (39.6%) patients had normal BP as defined by WHO/ISH. 2 For those on monotherapy, 23 (45.1%) had normalized BP compared to 66 (37.9%) on combination therapy. Of those without compelling indications, 62 (40.3%) had normalized BP, compared to 27 (38%) of those with compelling indications. The frequency of normal BP by presence of specific comorbidity was as follows: HF 7 (70%), DM 8 (36%), LVH 19 (28%), CVD 4 (30%) and CKD 4 (31%). Table 1 shows the mean monthly costs and the CER of the frequently used drugs. The most costeffective drug was the FDC diuretic co-amiloride with average monthly cost of 268.13 (US$ 1.99), and CER of 42.9. This was thus regarded as the reference CER and converted to a value of 1 to allow the CER relative to the most cost-effective therapy (relative CER) to be described. The least costeffective combination was CCB with ACEI (mean monthly acquisition cost 3276.25 (US$ 24.24) CER 3145.2, and relative CER 73.3).
The baseline characteristics of black patients attending this tertiary hypertension clinic in a developing country are those of a predominantly middle-aged, low-income population with long duration of hypertension and frequently co-existing compelling indications for control of BP. The rate of comorbid ischaemic heart disease was relatively lower than for other cardiovascular diseases (e.g. stroke and CKD). The prevalence of ischaemic heart disease is low in most regions in Africa compared to economically developed countries, although the situation is rapidly changing owing to several factors, including trends in urbanization, changes in lifestyle and increasing frequency of coronary risk factors. 4 The frequency of LVH in our study population was high, and may represent as overestimation owing to the use of voltage-based criteria.
Majority of our patients were on combination therapy. There is a favourable disposition to combination therapy in recent years particularly in patients with more difficult to control BP (often encountered in tertiary or referral settings). 5 There is rational justification for such therapy because the multifactorial nature of hypertension is addressed, BP control and achievement of target BP tends to be better, and the risk of side effects owing to use of maximal doses of monotherapeutic agents is reduced. Furthermore, hypertension in black people runs an aggressive course and control is achieved with multiple drug therapy rather than monotherapy. 6 According to recently published guide-lines, most patients will require two or more antihypertensive drugs to achieve control. 7, 8 The observed trend regarding CCBs predominating as preferred drug overall is similar to reports from other hospitals with a primarily black population. 5 The low rate of normotension achieved by our patients on CCB monotherapy compared with other studies could be partially ascribed to a myriad of generic forms of nifedipine available in the market, the standard and efficacy of which cannot be guaranteed. Although diuretics were not commonly prescribed as first line monotherapy, the percentage of patients with controlled hypertension was highest in this group and also in the group with diureticbased regimen. The ALLHAT trial has demonstrated the efficacy of thiazide diuretics in the reduction of cardiovascular mortality compared with amlodipine and ACEIs and this may modify practice once these findings are widely disseminated. 9 Recent guidelines have re-affirmed the efficacy of diuretics and diuretic-based combinations over other classes of antihypertensive drugs. 7, 8 Centrally acting drugs are still frequently used in our setting probably because they are cheap and yet effective. In contrast, centrally acting drugs were rarely prescribed in a study from South Africa 10 where the gross domestic product is higher and medical insurance is available. WHO/ISH made provision for the use of these drugs in countries with poor resources. 2 ACEIs were less frequently used in general in this cohort, but the percentage of those using ACEI increased considerably in the group with compelling indications. This represents an increased tendency towards the use of ACEI compared with a previous study carried out in a tertiary hospital within the same geographic location over a decade ago. 11 Several clinical trials have shown the efficacy of ACEI in reducing the overall CVD risk in different clinical settings. Despite the higher acquisition cost of ACEI, these drugs should be given appropriate consideration in patients in whom their use would appreciably improve outcomes. We however consider that availability of well-tested generic forms of these medications in developing economies would improve the individual patient's compliance and result in the desired effect, as recommended by the IFHA guidelines. 8 Low rates of utilization of b-blockers in Nigerians may be in consideration of findings that black people with hypertension are poorly responsive to these classes of drugs, whereas the efficacy of CCBs and diuretics in lowering BP in black population is well established. 8 However, b-blockers are frequently employed in those with CKD and some forms of arrhythmias in our practice.
Diuretics alone or in combination were the most cost-effective treatment in this study. This conforms to recent clinical trials (such as ALLHAT) that affirms the efficacy of diuretics and based combinations in effectively lowering BP and in reducing overall CVD risks. 8, 9 Diuretics have also been shown to be very effective in black hypertensive patients who have low renin, volume-dependant hypertension. The least cost-effective monotherapy and combination therapy were ACEI and ACEI plus CCB. ACEI monotherapy has not been shown to be effective in black patients. 9 One limitation of this study is the small number of patients on these classes of antihypertensive, a larger number would allow for more valid comparison. High acquisition cost may have contributed to the apparently lower efficacy.
Overall, the degree of BP control (overall 39.6; 41.5% on monotherapy and 37.9% on combination) is above the previously reported community-based nationwide trend of only a third of Nigerian hypertensives on treatment achieving BP control. 12 The degree of control in our study is similar to reports from another tertiary centre in Nigeria. 5 The BP control is however still unacceptably low, and improvements in BP control are desirable to reduce CVD morbidity and mortality in our centre.
In conclusion, this study serves to highlight the status of antihypertensive pharmacotherapy in a tertiary health institution in a developing African nation. While we await improvements in the economy, health insurance and welfare system, advances in control of BP in our population can be made by reducing acquisition costs through utilization of cheaper yet equally effective drug combinations like diuretics or diuretic-based combinations. We also advocate the use of genuine generic forms of the newer classes of antihypertensive drugs in those with compelling clinical indications for the use of these agents. We propose the development of treatment protocols (that will be periodically upgraded and audited) by hospitals based on sound scientific evidence, local availability and acquisition cost.
